Prevnar 13 – USA

Prevnar 13 – USA

IPR decision (Jun. 08, 2018):

AIA Review
Institution Date
Petitioner
Patent No.
Final Written Decision
IPR2017-00378; &
June 13, 2017
Merck Sharp & Dohme Corp
8,562,999
Claims 1–6, 10, 11, 14, 17, 19, 20 are unpatentable & claim 18 is patentable
IPR2017-00380
June 13, 2017
Merck Sharp & Dohme Corp
8,562,999
Claims 1–6, 10, 11, 14, 17, 19, 20 are unpatentable & claim 18 is patentable
IPR2017-00390
June 13, 2017
Merck Sharp & Dohme Corp
8,562,999
claims 7–9, 12, 13, 15, 16, 21, and 22 are unpatentable
US 8,562,999 claims  formulation comprising (i) a pH buffered saline solution with pKa of about 3.5 to about 7.5, (ii) an aluminum salt and (iii) one or more polysaccharide-protein conjugates, wherein the formulation is comprised in a siliconized container means and inhibits aggregation induced by the siliconized container means.

This patent is related to Pfizer Inc.’s top-selling Prevnar 13 pneumonia vaccine.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved